Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer

Published:2024-04-18 Issue:9 Volume:51 Page:2784-2793
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Song Hong,Leonio Maria Isabel,Ferri Valentina,Duan Heying,Aparici Carina Mari,Davidzon Guido,Franc Benjamin L.,Moradi Farshad,Shah Jagruti,Bergstrom Colin P.,Fan Alice C.,Shah Sumit,Khaki Ali Raza,Srinivas Sandy,Iagaru Andrei^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00259-024-06718-6.pdf

Reference30 articles.

1. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385:1091–103.

2. Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804.

3. Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33.

4. Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, et al. A systematic review and Meta-analysis of the effectiveness and toxicities of Lutetium-177-labeled prostate-specific membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-resistant prostate Cancer. Eur Urol. 2021;80:82–94.

5. Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, et al. Novel Framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate Cancer (RECIP 1.0): an International Multicenter Study. J Nucl Med. 2022;63:1651–8.